These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36593601)

  • 21. Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma.
    Jimenez-Zepeda VH; Duggan P; Neri P; Tay J; Bahlis NJ
    Ann Hematol; 2017 Mar; 96(3):431-439. PubMed ID: 28074255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
    Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
    Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma.
    Reeder CB; Reece DE; Kukreti V; Chen C; Trudel S; Laumann K; Hentz J; Pirooz NA; Piza JG; Tiedemann R; Mikhael JR; Bergsagel PL; Leis JF; Fonseca R; Stewart AK
    Blood; 2010 Apr; 115(16):3416-7. PubMed ID: 20413666
    [No Abstract]   [Full Text] [Related]  

  • 24. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
    Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
    Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma.
    Huang SX; Luo PH; Wang HL; Mo DC; Huang JF
    J Clin Oncol; 2023 May; 41(14):2667-2668. PubMed ID: 36940404
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
    Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
    Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
    Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
    Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
    Hashimoto S; Kuroha T; Yano T; Sato N; Furukawa T
    Intern Med; 2016; 55(20):3025-3028. PubMed ID: 27746443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
    Mikhael JR; Schuster SR; Jimenez-Zepeda VH; Bello N; Spong J; Reeder CB; Stewart AK; Bergsagel PL; Fonseca R
    Blood; 2012 May; 119(19):4391-4. PubMed ID: 22331188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
    Dolph M; Tremblay G; Leong H
    Pharmacoeconomics; 2021 Nov; 39(11):1309-1325. PubMed ID: 34368938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Multiple Myeloma With Daratumumab in a Kidney Transplant Patient.
    Yang D; Agrawal N; Marcus C; Roy N; Richards KR; Nahas MR; Cardarelli F
    Am J Ther; 2021 Jul-Aug 01; 28(4):e488-e491. PubMed ID: 34228654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Successful Treatment with Pomalidomide, Bortezomib, and Dexamethasone in a Patient with Frail Refractory and Relapsed Multiple Myeloma with Extramedullary Disease].
    Oka S; Takeuchi S; Shiragami H; Shimazu Y; Shimazu Y; Nougawa M
    Gan To Kagaku Ryoho; 2018 Dec; 45(12):1779-1782. PubMed ID: 30587741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CyBorD induction therapy in clinical practice.
    Areethamsirikul N; Masih-Khan E; Chu CM; Jimenez-Zepeda V; Reece DE; Trudel S; Kukreti V; Tiedemann R; Chen C
    Bone Marrow Transplant; 2015 Mar; 50(3):375-9. PubMed ID: 25599165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
    Reeder CB; Reece DE; Kukreti V; Chen C; Trudel S; Hentz J; Noble B; Pirooz NA; Spong JE; Piza JG; Zepeda VH; Mikhael JR; Leis JF; Bergsagel PL; Fonseca R; Stewart AK
    Leukemia; 2009 Jul; 23(7):1337-41. PubMed ID: 19225538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
    Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
    Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.
    Stork M; Sandecká V; Boichuk I; Adam Z; Krejci M; Brozova L; Sevcikova S; Pour L
    Klin Onkol; 2019; 32(6):445-452. PubMed ID: 31842563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study.
    Kropff M; Vogel M; Bisping G; Schlag R; Weide R; Knauf W; Fiechtner H; Kojouharoff G; Kremers S; Berdel WE
    Ann Hematol; 2017 Nov; 96(11):1857-1866. PubMed ID: 28905189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.